Peering Into Esperion Therapeutics's Recent Short Interest
Portfolio Pulse from Benzinga Insights
Esperion Therapeutics (NYSE:ESPR) has seen a significant decrease in short interest, with a 40.03% drop since the last report. The current short interest stands at 20.20 million shares, or 12.66% of the float. It would take about 2.65 days to cover all short positions. While a decrease in short interest can indicate a more bullish sentiment, it does not necessarily predict a near-term rise in stock price. Esperion has a higher short interest than its peer group average of 10.42%.
January 30, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Esperion Therapeutics's short interest has significantly decreased, which may indicate a more bullish sentiment among investors. However, this does not guarantee an immediate increase in stock price.
A decrease in short interest typically suggests that investors are less bearish on the stock, which could lead to a short-term price increase. However, the impact is not certain as short interest is just one of many factors that influence stock prices.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 100